Functionally, the IL-6/JAK/STAT3 signaling axis promotes proliferation, angiogenesis, EMT, and the cancer stem cell (CSC) subpopulation, while concurrently suppressing the antitumor immune response (87–90). Here, STAT3 is linked to cancer.